- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01435265
Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab
The Effectiveness of Nurse Education and Its Impact on Treatment Adherence in Subjects With Moderate to Severe Psoriasis Undergoing Treatment With Adalimumab
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a phase IV randomized, prospective open label study to asses the efficacy of an extended nurse eduction program in improving adherence to the prescribed treatment regimen in the treatment of moderate to severe psoriasis vulgaris. Twenty subjects, male or female, ages 18 and older in good health with moderate to severe chronic plaque type psoriasis for whom adalimumab is indicated according to the adalimumab prescribing information. All subjects must have a negative TB skin test according to prescribing guidelines. Subjects must be starting adalimumab for the first time, prescribed by their physician.
This is an open label trial. All subjects will be receiving adalimumab as prescribed by their physician. Half the group will be randomized to receive the additional nurse education program, the other half will receive the normal education materials provided by their physician.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27157
- Wake Forest University Health Sciences
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subjects must be male or female, 18 years of age or greater, in good health with moderate to severe plaque psoriasis for whom adalimumab is indicated according to the adalimumab prescribing information.
- All subjects must have a negative TB skin test according to prescribing guidelines.
- Subjects must be starting adalimumab for the first time, prescribed by their dermatologist.
- Must give written informed consent.
- Subject must be adult males or non-pregnant , non-lactating females.
- Female subjects of childbearing potential must state that they are using measures to avoid conception through active means including, abstinence, oral contraceptives, intrauterine device, Depo-Provera, Norplant, tubal ligation, or vasectomy of the partner in a monogamous relationship.
- Subjects may not be on concomitant systemic medications for their psoriasis such as methotrexate, acitretin, etretinate, cyclosporine, prednisone ot other biological agents or receiving phototherapy at the baseline visit, but no specific washout of these treatments will be required.
- There is no washout for topical medications. Stable dosing of topical medications may be used throughout the duration of the study.
Exclusion Criteria:
- Subjects who have any skin condition or disease that may require concurrent therapy or may confound the evaluation.
- Subjects who have a history of hypersensitivity to adalimumab or history of hypersensitivity to any of the formulation components will be excluded from the study.
- Female subjects who are not postmenopausal for at least one year, surgically sterile or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.
- Current enrollment in any research study involving an investigational drug.
- Serious local infection or systemic infection within the three months prior to the first dose of investigational drug.
- Treatment with another investigational drug within one month prior to study drug administration.
- Concurrent treatment with systemic retinoids, systemic steroids, methotrexate, cyclosporine, azathioprine, thioguanine, etanercept, efalizumab, infliximab or mofetil or other systemic immunosuppressant agents.
- Any active or history of HIV, Hepatitis or tuberculosis
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Normal Nurse Education
Subjects receive normal nurse education materials provided by their physician.
|
Standard-of-care education from a dermatology nurse on the proper use of adalimumab
|
Eksperimentell: Additional Nurse Education-
Subjects will receive additional nurse education beyond the normal education materials provided by their physician
|
Standard-of-care education from a dermatology nurse on the proper use of adalimumab
Additional education from a nurse on the use of adalimumab.
This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit.
Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided.
Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided.
Subjects will also receive reminder phone calls to take each scheduled dose.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change in Psoriasis Area Severity Index (PASI-75)
Tidsramme: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
|
The Psoriasis Area Severity Index measures severity of psoriasis on a 0-6 scale for head, trunk, upper extremities, and lower extremities and amount of erythema, infiltration, and desquamation for each area.
An overall score of 0-72 for the whole body is calculated from the observed severity values.
Outcomes will be reported in terms of PASI 75, or number of participants showing at least 75% reduction in PASI score from baseline.
Only final PASI 75 will be reported.
|
Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
|
Investigator's Global Assessment (IGA) of Psoriasis
Tidsramme: 12 months
|
Investigator's Global Assessment (IGA) is rated on a scale of 0 (clear) to 5 (very severe).
The outcome measure to be reported is the number of patients who reached a final IGA of 0 (clear) or 1 (almost clear).
|
12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Adherence to Adalimumab Treatment
Tidsramme: Baseline to 12 months
|
Adherence measured by average days between doses used, as measured by a Medication Event Monitoring System (MEMS) cap on the disposal container for used syringes.
|
Baseline to 12 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Steven R Feldman, MD, PhD, Wake Forest University Health Sciences
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB00009876
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Psoriasis
-
ProgenaBiomeRekrutteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hodebunnen | Psoriatisk plakk | Psoriasis Universalis | Psoriasis ansikt | Psoriasis negl | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaForente stater
-
Clin4allRekrutteringPsoriasis i hodebunnen | Psoriasis negl | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrankrike
-
Centre of Evidence of the French Society of DermatologyRekrutteringPsoriasis | Psoriasis Vulgaris | Psoriasis i hodebunnen | Psoriatisk plakk | Psoriasis Universalis | Psoriasis Palmaris | Psoriatisk erytrodermi | Psoriasis negl | Psoriasis Guttate | Psoriasis invers | Psoriasis pustulærFrankrike
-
AmgenFullførtPsoriasis-type psoriasis | Plakk-type psoriasisForente stater
-
Innovaderm Research Inc.FullførtPsoriasis i hodebunnen | Pustuløs Palmo-plantar Psoriasis | Ikke-pustulær Palmo-plantar Psoriasis | Psoriasis i albuen | Psoriasis i underbenetCanada
-
UCB Biopharma S.P.R.L.FullførtModerat til alvorlig psoriasis | Generalisert pustuløs psoriasis og erytrodermisk psoriasisJapan
-
Janssen Pharmaceutical K.K.RekrutteringGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
Eli Lilly and CompanyFullførtGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
TakedaRekrutteringGeneralisert pustulær psoriasis | Erytrodermisk psoriasisJapan
-
PfizerFullførtPsoriasis Vulgaris | Pustuløs psoriasis | Psoriasis Arthropathica | Erytrodermisk psoriasisJapan
Kliniske studier på Standard nurse education
-
Lisa CarlessoHar ikke rekruttert ennåArtrose | Kronisk smerte
-
Ahi Evran University Education and Research HospitalFullført
-
Hacettepe UniversityRekruttering
-
University of BolognaFullført
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); Canadian Center for Vaccinology og andre samarbeidspartnereFullført
-
University of MalayaFullførtTrykkskade | Begrensning, MobilitetMalaysia
-
University of Alabama at BirminghamRekrutteringType 2 diabetesForente stater
-
McMaster UniversityBoston University; University of British Columbia; University of MelbourneRekruttering